{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:02:20Z","timestamp":1790456540596,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jhltopen.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHLT Open"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jhlto.2025.100210","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T19:59:11Z","timestamp":1737230351000},"page":"100210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evaluation of Elexacafor\/Tezacaftor\/Ivacaftor therapy after lung transplantation in Cystic Fibrosis: The Dutch National KOALA study"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-9767","authenticated-orcid":false,"given":"Johanna P.","family":"van Gemert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Luijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel E.","family":"Hellemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara A.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1468-0103","authenticated-orcid":false,"given":"Carina.M.E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Tji","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"van der Vaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-9260","authenticated-orcid":false,"given":"Onno W.","family":"Akkerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie N.","family":"Steenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2787-5440","authenticated-orcid":false,"given":"Marieke","family":"Verkleij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry G.M.","family":"Heijerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-6744","authenticated-orcid":false,"given":"Erik A.M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jhlto.2025.100210_bib1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jhlto.2025.100210_bib2","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"The Lancet"},{"issue":"18","key":"10.1016\/j.jhlto.2025.100210_bib3","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jhlto.2025.100210_bib4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcf.2021.05.009","article-title":"Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease","volume":"20","author":"B","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jhlto.2025.100210_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.jhlto.2025.100210_bib6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jhlto.2025.100210_bib7","unstructured":"Kaftrio. Summary of Product Characteristics. Accessed June 18, 2024. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/kaftrio-epar-product-information\u3009."},{"issue":"1","key":"10.1016\/j.jhlto.2025.100210_bib8","doi-asserted-by":"crossref","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jhlto.2025.100210_bib9","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","article-title":"Development and validation of the cystic fibrosis questionnaire in the United States","volume":"128","author":"Quittner","year":"2005","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jhlto.2025.100210_bib10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22\u2013item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.jhlto.2025.100210_bib11","unstructured":"Verkleij M. VBBHGTJQA de M. The Dutch Gastrointestinal (GI) Symptom Tracker for People with Cystic Fibrosis: Associations with anxiety, depression and health-related quality of life. In Press."},{"issue":"S47","key":"10.1016\/j.jhlto.2025.100210_bib12","article-title":"Psychometric analyses of a new gi symptom tracker for cystic fibrosis","volume":"52","author":"Quittner","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jhlto.2025.100210_bib13","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/S1569-1993(22)00576-8","article-title":"P247 Dutch translation of the gastrointestinal (GI) symptom tracker for people with cystic fibrosis (CF)","volume":"21","author":"Verkleij","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jhlto.2025.100210_bib14","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1002\/lary.31438","article-title":"Predictors of sinonasal improvement after highly effective modulator therapy in adults with cystic fibrosis","volume":"134","author":"Beswick","year":"2024","journal-title":"Laryngoscope"},{"issue":"7","key":"10.1016\/j.jhlto.2025.100210_bib15","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"issue":"12","key":"10.1016\/j.jhlto.2025.100210_bib16","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.healun.2021.08.009","article-title":"CFTR modulator use in post lung transplant recipients","volume":"40","author":"Benninger","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.jhlto.2025.100210_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14007","article-title":"To treat or not to treat: CFTR modulators after lung transplantation","volume":"25","author":"Hayes","year":"2021","journal-title":"Pediatr Transplant"},{"issue":"5","key":"10.1016\/j.jhlto.2025.100210_bib18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jhlto.2025.100210_bib19","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1007\/s00405-023-08028-3","article-title":"Impact of extended sinus surgery on allograft infection, allograft function and overall survival in cystic fibrosis lung transplant recipients","volume":"280","author":"Meier","year":"2023","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"7","key":"10.1016\/j.jhlto.2025.100210_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11908-016-0529-6","article-title":"Infectious triggers of chronic lung allograft dysfunction","volume":"18","author":"Gregson","year":"2016","journal-title":"Curr Infect Dis Rep"},{"issue":"3","key":"10.1016\/j.jhlto.2025.100210_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jcf.2024.01.008","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study","volume":"23","author":"van der Meer","year":"2024","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1016\/j.jhlto.2025.100210_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.17219\/acem\/35254","article-title":"The effect of P-glycoprotein inhibition and activation on the absorption and serum levels of cyclosporine and tacrolimus in rats","volume":"25","author":"Yigitaslan","year":"2016","journal-title":"Adv Clin Exp Med"},{"issue":"6","key":"10.1016\/j.jhlto.2025.100210_bib23","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"}],"container-title":["JHLT Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950133425000059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950133425000059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T08:19:11Z","timestamp":1739175551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950133425000059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":23,"alternative-id":["S2950133425000059"],"URL":"https:\/\/doi.org\/10.1016\/j.jhlto.2025.100210","relation":{},"ISSN":["2950-1334"],"issn-type":[{"value":"2950-1334","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Elexacafor\/Tezacaftor\/Ivacaftor therapy after lung transplantation in Cystic Fibrosis: The Dutch National KOALA study","name":"articletitle","label":"Article Title"},{"value":"JHLT Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhlto.2025.100210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}],"article-number":"100210"}}